Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection
This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further in...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2011-12, Vol.53 (11), p.1111-1114 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1114 |
|---|---|
| container_issue | 11 |
| container_start_page | 1111 |
| container_title | Clinical infectious diseases |
| container_volume | 53 |
| creator | Wiegand, Johannes Neumann, Konrad Böhm, Stephan Weich, Viola Teuber, Gerlinde Klinker, Hartwig Möller, Bernd Rasenack, Jens Hinrichsen, Holger Gerlach, Tilman Spengler, Ulrich Buggisch, Peter Sarrazin, Christoph Berg, Thomas |
| description | This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further individualize new protease inhibitor-based triple therapy regimens. |
| doi_str_mv | 10.1093/cid/cir670 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_902086720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>41328221</jstor_id><oup_id>10.1093/cid/cir670</oup_id><sourcerecordid>41328221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-a30bc3c14ad94ae912b5123a34066d883d7cdd87dd2199a392d8e02a0f79946c3</originalsourceid><addsrcrecordid>eNp90c1LHDEUAPAgLX61l95bgiCCMG0-ZjLJUZaqC4pS-nEcsskbzDKTjEmG4n9vdFeFHnoIeTx-eUneQ-gTJV8pUfybcbasKFqyg_Zpw9tKNIq-KzFpZFVLLvfQQUprQiiVpNlFe4wRRhVV--jvcpxCzNobwKHH1867UQ_4ByRn5xL8dhFGp3EfYkkOekqAbyNYZ7ILHjuPb3V24HPCf1y-w4u7GLwz-BKmks8u4QW-AB_ywwSY4qXv4fnkB_S-10OCj9v9EP06__5zcVld3VwsF2dXlak5zZXmZGW4obW2qtagKFs1lHHNayKElZLb1lgrW2vLf5TmilkJhGnSt0rVwvBDdLKpO8VwP0PK3eiSgWHQHsKcOkUYkaJlpMijf-Q6zNGXxz0hygQTbUGnG2RiSClC302xNCw-dJR0T8PoyjC6zTAK_rKtOK9GsK_0pfsFHG-BTkYPfSxjcOnNNawhTDRvLszT_y_8vHHrlEN8lTXlTDJG-SNncKgy</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>902126267</pqid></control><display><type>article</type><title>Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection</title><source>MEDLINE</source><source>JSTOR Archive Collection A-Z Listing</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Wiegand, Johannes ; Neumann, Konrad ; Böhm, Stephan ; Weich, Viola ; Teuber, Gerlinde ; Klinker, Hartwig ; Möller, Bernd ; Rasenack, Jens ; Hinrichsen, Holger ; Gerlach, Tilman ; Spengler, Ulrich ; Buggisch, Peter ; Sarrazin, Christoph ; Berg, Thomas</creator><creatorcontrib>Wiegand, Johannes ; Neumann, Konrad ; Böhm, Stephan ; Weich, Viola ; Teuber, Gerlinde ; Klinker, Hartwig ; Möller, Bernd ; Rasenack, Jens ; Hinrichsen, Holger ; Gerlach, Tilman ; Spengler, Ulrich ; Buggisch, Peter ; Sarrazin, Christoph ; Berg, Thomas</creatorcontrib><description>This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further individualize new protease inhibitor-based triple therapy regimens.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/cir670</identifier><identifier>PMID: 22021919</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject><![CDATA[Antiviral Agents - administration & dosage ; Biological and medical sciences ; Branched DNA signal amplification assay ; BRIEF REPORTS ; Chronic hepatitis ; Drug therapy ; Genotype ; Genotype & phenotype ; Genotypes ; Hepacivirus - classification ; Hepacivirus - genetics ; Hepacivirus - isolation & purification ; Hepatitis ; Hepatitis C ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - virology ; Human viral diseases ; Humans ; Individualization ; Infections ; Infectious diseases ; Interferon-alpha - administration & dosage ; Kinetics ; Medical sciences ; Polyethylene Glycols - administration & dosage ; Recombinant Proteins - administration & dosage ; Recurrence ; Relapse ; Ribavirin - administration & dosage ; Risk Assessment ; RNA ; Viral diseases ; Viral hepatitis ; Viral Load ; Viremia ; Virology ; Viruses]]></subject><ispartof>Clinical infectious diseases, 2011-12, Vol.53 (11), p.1111-1114</ispartof><rights>Copyright © 2011 Oxford University Press</rights><rights>The Author 2011. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com. 2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Dec 1, 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-a30bc3c14ad94ae912b5123a34066d883d7cdd87dd2199a392d8e02a0f79946c3</citedby><cites>FETCH-LOGICAL-c431t-a30bc3c14ad94ae912b5123a34066d883d7cdd87dd2199a392d8e02a0f79946c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/41328221$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/41328221$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,803,1584,27924,27925,58017,58250</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25250265$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22021919$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wiegand, Johannes</creatorcontrib><creatorcontrib>Neumann, Konrad</creatorcontrib><creatorcontrib>Böhm, Stephan</creatorcontrib><creatorcontrib>Weich, Viola</creatorcontrib><creatorcontrib>Teuber, Gerlinde</creatorcontrib><creatorcontrib>Klinker, Hartwig</creatorcontrib><creatorcontrib>Möller, Bernd</creatorcontrib><creatorcontrib>Rasenack, Jens</creatorcontrib><creatorcontrib>Hinrichsen, Holger</creatorcontrib><creatorcontrib>Gerlach, Tilman</creatorcontrib><creatorcontrib>Spengler, Ulrich</creatorcontrib><creatorcontrib>Buggisch, Peter</creatorcontrib><creatorcontrib>Sarrazin, Christoph</creatorcontrib><creatorcontrib>Berg, Thomas</creatorcontrib><title>Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further individualize new protease inhibitor-based triple therapy regimens.</description><subject>Antiviral Agents - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Branched DNA signal amplification assay</subject><subject>BRIEF REPORTS</subject><subject>Chronic hepatitis</subject><subject>Drug therapy</subject><subject>Genotype</subject><subject>Genotype & phenotype</subject><subject>Genotypes</subject><subject>Hepacivirus - classification</subject><subject>Hepacivirus - genetics</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis</subject><subject>Hepatitis C</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - virology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Individualization</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Interferon-alpha - administration & dosage</subject><subject>Kinetics</subject><subject>Medical sciences</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Recombinant Proteins - administration & dosage</subject><subject>Recurrence</subject><subject>Relapse</subject><subject>Ribavirin - administration & dosage</subject><subject>Risk Assessment</subject><subject>RNA</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>Viral Load</subject><subject>Viremia</subject><subject>Virology</subject><subject>Viruses</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90c1LHDEUAPAgLX61l95bgiCCMG0-ZjLJUZaqC4pS-nEcsskbzDKTjEmG4n9vdFeFHnoIeTx-eUneQ-gTJV8pUfybcbasKFqyg_Zpw9tKNIq-KzFpZFVLLvfQQUprQiiVpNlFe4wRRhVV--jvcpxCzNobwKHH1867UQ_4ByRn5xL8dhFGp3EfYkkOekqAbyNYZ7ILHjuPb3V24HPCf1y-w4u7GLwz-BKmks8u4QW-AB_ywwSY4qXv4fnkB_S-10OCj9v9EP06__5zcVld3VwsF2dXlak5zZXmZGW4obW2qtagKFs1lHHNayKElZLb1lgrW2vLf5TmilkJhGnSt0rVwvBDdLKpO8VwP0PK3eiSgWHQHsKcOkUYkaJlpMijf-Q6zNGXxz0hygQTbUGnG2RiSClC302xNCw-dJR0T8PoyjC6zTAK_rKtOK9GsK_0pfsFHG-BTkYPfSxjcOnNNawhTDRvLszT_y_8vHHrlEN8lTXlTDJG-SNncKgy</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Wiegand, Johannes</creator><creator>Neumann, Konrad</creator><creator>Böhm, Stephan</creator><creator>Weich, Viola</creator><creator>Teuber, Gerlinde</creator><creator>Klinker, Hartwig</creator><creator>Möller, Bernd</creator><creator>Rasenack, Jens</creator><creator>Hinrichsen, Holger</creator><creator>Gerlach, Tilman</creator><creator>Spengler, Ulrich</creator><creator>Buggisch, Peter</creator><creator>Sarrazin, Christoph</creator><creator>Berg, Thomas</creator><general>Oxford University Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection</title><author>Wiegand, Johannes ; Neumann, Konrad ; Böhm, Stephan ; Weich, Viola ; Teuber, Gerlinde ; Klinker, Hartwig ; Möller, Bernd ; Rasenack, Jens ; Hinrichsen, Holger ; Gerlach, Tilman ; Spengler, Ulrich ; Buggisch, Peter ; Sarrazin, Christoph ; Berg, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-a30bc3c14ad94ae912b5123a34066d883d7cdd87dd2199a392d8e02a0f79946c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antiviral Agents - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Branched DNA signal amplification assay</topic><topic>BRIEF REPORTS</topic><topic>Chronic hepatitis</topic><topic>Drug therapy</topic><topic>Genotype</topic><topic>Genotype & phenotype</topic><topic>Genotypes</topic><topic>Hepacivirus - classification</topic><topic>Hepacivirus - genetics</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis</topic><topic>Hepatitis C</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - virology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Individualization</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Interferon-alpha - administration & dosage</topic><topic>Kinetics</topic><topic>Medical sciences</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Recombinant Proteins - administration & dosage</topic><topic>Recurrence</topic><topic>Relapse</topic><topic>Ribavirin - administration & dosage</topic><topic>Risk Assessment</topic><topic>RNA</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>Viral Load</topic><topic>Viremia</topic><topic>Virology</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wiegand, Johannes</creatorcontrib><creatorcontrib>Neumann, Konrad</creatorcontrib><creatorcontrib>Böhm, Stephan</creatorcontrib><creatorcontrib>Weich, Viola</creatorcontrib><creatorcontrib>Teuber, Gerlinde</creatorcontrib><creatorcontrib>Klinker, Hartwig</creatorcontrib><creatorcontrib>Möller, Bernd</creatorcontrib><creatorcontrib>Rasenack, Jens</creatorcontrib><creatorcontrib>Hinrichsen, Holger</creatorcontrib><creatorcontrib>Gerlach, Tilman</creatorcontrib><creatorcontrib>Spengler, Ulrich</creatorcontrib><creatorcontrib>Buggisch, Peter</creatorcontrib><creatorcontrib>Sarrazin, Christoph</creatorcontrib><creatorcontrib>Berg, Thomas</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wiegand, Johannes</au><au>Neumann, Konrad</au><au>Böhm, Stephan</au><au>Weich, Viola</au><au>Teuber, Gerlinde</au><au>Klinker, Hartwig</au><au>Möller, Bernd</au><au>Rasenack, Jens</au><au>Hinrichsen, Holger</au><au>Gerlach, Tilman</au><au>Spengler, Ulrich</au><au>Buggisch, Peter</au><au>Sarrazin, Christoph</au><au>Berg, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>53</volume><issue>11</issue><spage>1111</spage><epage>1114</epage><pages>1111-1114</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia at weeks 4, 8, and 12 in combination with levels of baseline viremia. These data may also help to further individualize new protease inhibitor-based triple therapy regimens.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>22021919</pmid><doi>10.1093/cid/cir670</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2011-12, Vol.53 (11), p.1111-1114 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_902086720 |
| source | MEDLINE; JSTOR Archive Collection A-Z Listing; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antiviral Agents - administration & dosage Biological and medical sciences Branched DNA signal amplification assay BRIEF REPORTS Chronic hepatitis Drug therapy Genotype Genotype & phenotype Genotypes Hepacivirus - classification Hepacivirus - genetics Hepacivirus - isolation & purification Hepatitis Hepatitis C Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - virology Human viral diseases Humans Individualization Infections Infectious diseases Interferon-alpha - administration & dosage Kinetics Medical sciences Polyethylene Glycols - administration & dosage Recombinant Proteins - administration & dosage Recurrence Relapse Ribavirin - administration & dosage Risk Assessment RNA Viral diseases Viral hepatitis Viral Load Viremia Virology Viruses |
| title | Importance of Minimal Residual Viremia for Relapse Prediction in Patients With Chronic Hepatitis C Genotype 1 Infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T03%3A32%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Importance%20of%20Minimal%20Residual%20Viremia%20for%20Relapse%20Prediction%20in%20Patients%20With%20Chronic%20Hepatitis%20C%20Genotype%201%20Infection&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Wiegand,%20Johannes&rft.date=2011-12-01&rft.volume=53&rft.issue=11&rft.spage=1111&rft.epage=1114&rft.pages=1111-1114&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1093/cid/cir670&rft_dat=%3Cjstor_proqu%3E41328221%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=902126267&rft_id=info:pmid/22021919&rft_jstor_id=41328221&rft_oup_id=10.1093/cid/cir670&rfr_iscdi=true |